Search Job Title Only
Treasury & Bonds
View Full List
Dow Jones Industrial Average
Standard & Poors 500
NYSE COMPOSITE INDX
December 13, 2012 at 08:47 AM EST
ArQule Enrolls First Patient in Phase 1 Trial with ARQ 087
ArQule, Inc. (Nasdaq: ARQL ) today announced the commencement of patient dosing in a Phase 1 clinical trial with ARQ 087, an orally bioavailable, potent multi-kinase inhibitor with pan-FGFR (fibroblast growth factor receptor) activity. The primary objective of the Phase 1 trial with ARQ 087 is determine its safety, tolerability and recommended Phase 2
Read More >>
Stock Market XML and JSON Data API
provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays.
Stock Market Holiday List
By accessing this page, you agree to the following
Terms and Conditions
Press Release Service
provided by PRConnect.
Stock quotes supplied by Six Financial
Bots go here